“And upon coverage, this will be an immediate growth driver and will become a significant source of growth for the company.”

In context

“f our first micro leadless pacemaker receiving CE mark. And now, a decade later, our micro-franchise continues to set the standard, delivering outstanding 24% growth in Q3, and we expect this strength to continue. Now turning to hypertension and our simplicity blood pressure procedure. We're poised to change the standard-of-care for uncontrolled high blood pressure. Medicare coding and payment is now in place and just last month we had a pivotal development when CMS opened a national coverage analysis. This is exciting news, as we will now have Medicare coverage in place within the next eight months. We're activating new accounts across the U.S. and helping them set up simplicity clinics and establish care pathways, so they're prepared to quickly ramp procedures when coverage is in place. And upon coverage, this will be an immediate growth driver and will become a significant source of growth for the company. Nearly half of U.S. adults have hypertension, and one in four of those with hypertension, they just don't have it under control, despite the broad availability of numerous generic medications. So as we take a step back, the patient population is large. The current standard of care is just isn't working. Patients want this new therapy. Physicians can easily do the procedure, and health systems support it. The opportunity here is just massive, and we're poised to be the leader in addressing this large and unmet need. And as we look at the overall cardiovascular portfolio, taking all of these growth drivers together, we expect its growth to meaningfully accelerate in the quarters ahead, starting with Q4. Turning to our neuroscience portfolio, which also grew mid-single-digits this quarter, i”